CRISPR Therapeutics’ (CRSP) Market Outperform Rating Reaffirmed at Citizens Jmp

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “market outperform” rating reiterated by Citizens Jmp in a research note issued to investors on Monday,Benzinga reports. They presently have a $80.00 price objective on the stock. Citizens Jmp’s price objective suggests a potential upside of 33.16% from the stock’s previous close.

A number of other research analysts have also weighed in on CRSP. Piper Sandler reissued an “overweight” rating and issued a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a report on Tuesday, March 17th. Wall Street Zen lowered shares of CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Sanford C. Bernstein lifted their price objective on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the stock an “equal weight” rating in a report on Thursday, June 11th. Finally, UBS Group set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $67.78.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $60.08 on Monday. The firm has a market cap of $5.79 billion, a PE ratio of -9.66 and a beta of 1.71. The stock has a 50 day moving average of $52.78 and a 200 day moving average of $53.05. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics has a 12 month low of $44.12 and a 12 month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. The firm had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%. On average, research analysts expect that CRISPR Therapeutics will post -4.89 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Naimish Patel sold 3,786 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the sale, the insider owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. This represents a 16.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds have recently added to or reduced their stakes in CRSP. Versant Capital Management Inc grew its stake in shares of CRISPR Therapeutics by 175.1% during the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock valued at $25,000 after buying an additional 296 shares during the last quarter. Mcguire Capital Advisors Inc. purchased a new position in CRISPR Therapeutics during the 4th quarter valued at $25,000. Ramirez Asset Management Inc. purchased a new position in CRISPR Therapeutics during the 4th quarter valued at $26,000. Strategic Advocates LLC bought a new position in CRISPR Therapeutics in the 3rd quarter valued at $34,000. Finally, Rothschild Investment LLC grew its position in CRISPR Therapeutics by 836.7% in the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after acquiring an additional 502 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.